Around 30 Indian institutions are working to develop a nCoV-19 vaccine

T V Jayan New Delhi | Updated on May 08, 2020 Published on May 08, 2020

According to the SERB official, academic and research institutions with strong interdisciplinary links with chemists, biologists, virologists, immunologists and clinicians can apply for the IRHPA funding

A few of them are expected to move into clinical trials later this year.

Indian pharma companies and research groups in different scientific laboratories are working on as many as 30 different novel Coronavirus (nCoV-19) vaccines, and a few of them are expected to move into clinical trials later this year.

While taking stock of India’s efforts in developing corona vaccines, drugs and diagnostics on Tuesday, Prime Minister Narendra Modi said that nearly 30 Indian vaccines are getting ready. While there are that many, those few in advanced stages of development are mainly those vaccines on which most initial developmental work was carried out elsewhere, shows information sourced from multiple sources.

For instance, the Pune-based Serum Institute is a manufacturing partner for a promising vaccine developed by the University of Oxford. Called ChAdOx1 nCoV-19, the vaccine uses a weakened version of the virus that causes the common cold in chimpanzees to carry particular genetic material from SARS-CoV2 virus which makes proteins that help the Covid-19 virus to human cells. The vaccine is already undergoing limited clinical trials in Oxford and is in an advanced stage of development.


Serum Institute is also involved in the development of three other nCoV-19 vaccines in collaboration with overseas firms or research institutes and one of them, a live attenuated vaccine, is expected to go to phase 1 trials in the third quarter of 2020.

Similarly, Hyderabad-based BharatBiotech International Limited in association with two US universities – the University of Wisconsin-Madison and Thomas Jefferson University -- is developing two different vaccines. The one jointly developed with the University of Wisconsin-Madison is a nasal vaccine and is expected to go to trials by later part of this year. The other which uses a rabies vaccine platform is also expected to hit Phase 1 trials by December this year.

Similarly, a major Indian pharma company Cadila Healthcare is gearing up to test a DNA vaccine for COVID-19 by November this year. Indian Immunological Limited, a subsidiary of National Dairy Development Board, similarly has a tie-up with Australian Griffith University, but this live attenuated vaccine will not be ready for testing till mid-2022.

Among other Indian pharma firms collaborating with overseas teams are Aurobindo Pharma Limited which tied up with Aurovaccines US and Biological E which is working with a team at Massachusetts Institute of Technology. There are a few lesser-known pharma firms and startups too in the nCoV vaccine fray, but most of them are in the early stages of development.

Besides these firms, many research groups in Indian laboratories such as National Institute of Immunology, New Delhi, Translational Health Science and Technology Institute, in Faridabad, National Centre for Cell Sciences, Pune, Indian Institute of Science Education and Research in Mohali as well as Thiruvananthapuram too are developing indigenous vaccines. However, they are very early stages of development.

Published on May 08, 2020

A letter from the Editor

Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Support Quality Journalism
  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.